EJCTS Click here for details of sales representative
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Eur J Cardiothorac Surg 2007;32:770-775. doi:10.1016/j.ejcts.2007.07.012
Copyright © 2007, European Association for Cardio-thoracic Surgery. Published by Elsevier. All rights reserved.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Minamiya, Y.
Right arrow Articles by Ogawa, J.-i.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Minamiya, Y.
Right arrow Articles by Ogawa, J.-i.
Related Collections
Right arrow Lung - cancer

Subpleural injection of tracer improves detection of mediastinal sentinel lymph nodes in non-small cell lung cancer

Yoshihiro Minamiya*, Manabu Ito, Yukiko Hosono, Hideki Kawai, Hajime Saito, Yoshihisa Katayose, Satoru Motoyama, Jun-ichi Ogawa

Division of Thoracic Surgery, Department of Surgery, Akita University School of Medicine, 1-1-1 Hondo Akita City 010-8543, Japan

Received 3 May 2007; received in revised form 27 June 2007; accepted 13 July 2007.

* Corresponding author. Tel.: +81 18 884 6132; fax: +81 18 836 2615. (Email: minamiya{at}med.akita-u.ac.jp).

Background: The advantages and disadvantages of various tracer injection protocols for sentinel lymph node (SLN) mapping have been extensively discussed in relation to breast and gastric cancer. But no such discussion has taken place in relation to SLN mapping in non-small cell lung cancer. We therefore studied the effect of two tracer injection protocols on SLN mapping in patients with non-small cell lung cancer; of particular interest was the relationship between subpleural tracer injection and identification of mediastinal SLNs. Methods: A quadrant injection group (n = 49) received 1.6 ml of ferucarbotran by peritumoral quadrant injection after thoracotomy. In the subpleural injection group, the same amount of ferucarbotran was injected into the peritumoral quadrants plus the subpleural region (n = 27). SLNs were then detected intraoperatively by measuring the magnetic force within lymph nodes using a hand-held magnetometer. After completing the SLN mapping, lobectomy and hilar and mediastinal lymph node dissection was performed. Results: The incidence of mediastinal SLNs was significantly higher in the subpleural injection group (45.4%) than in the quadrant injection group (14.6%) (p = 0.007). Moreover, nominal logistic regression analysis revealed subpleural injection to be a significant independent factor contributing to detection of mediastinal SLNs (p = 0.024, odds ratio 5.26). In the quadrant injection group, mediastinal lymph node metastasis was detected in two patients thought to have nonmetastatic parenchymal SLNs. By contrast, there were no false-negative cases in the subpleural injection group. Conclusion: Subpleural tracer injection significantly improves detection of mediastinal SLNs in non-small cell lung cancer.

Key Words: Lung cancer surgery • Lung cancer • Lymph nodes







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2007 European Association for Cardio-Thoracic Surgery. Published by Elsevier. All rights reserved.